DOXIMITY INC-CLASS A (DOCS) Stock Fundamental Analysis
NYSE:DOCS - New York Stock Exchange, Inc. - US26622P1075 - Common Stock - Currency: USD
Taking everything into account, DOCS scores 7 out of 10 in our fundamental rating. DOCS was compared to 37 industry peers in the Health Care Technology industry. DOCS scores excellent points on both the profitability and health parts. This is a solid base for a good stock. DOCS has a correct valuation and a medium growth rate. This makes DOCS very considerable for quality investing!
1. Profitability
1.1 Basic Checks
DOCS had positive earnings in the past year.
DOCS had a positive operating cash flow in the past year.
Of the past 5 years DOCS 4 years were profitable.
Of the past 5 years DOCS 4 years had a positive operating cash flow.
1.2 Ratios
With an excellent Return On Assets value of 17.18%, DOCS belongs to the best of the industry, outperforming 100.00% of the companies in the same industry.
DOCS has a Return On Equity of 19.53%. This is amongst the best in the industry. DOCS outperforms 100.00% of its industry peers.
The Return On Invested Capital of DOCS (17.38%) is better than 100.00% of its industry peers.
The Average Return On Invested Capital over the past 3 years for DOCS is significantly above the industry average of 6.39%.
The last Return On Invested Capital (17.38%) for DOCS is above the 3 year average (12.02%), which is a sign of increasing profitability.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 17.18% | ||
| ROE | 19.53% | ||
| ROIC | 17.38% |
ROA(3y)12.35%
ROA(5y)10.68%
ROE(3y)14.41%
ROE(5y)14.17%
ROIC(3y)12.02%
ROIC(5y)17.46%
1.3 Margins
DOCS's Profit Margin of 36.60% is amongst the best of the industry. DOCS outperforms 97.30% of its industry peers.
In the last couple of years the Profit Margin of DOCS has grown nicely.
DOCS has a Operating Margin of 40.58%. This is amongst the best in the industry. DOCS outperforms 100.00% of its industry peers.
DOCS's Operating Margin has improved in the last couple of years.
Looking at the Gross Margin, with a value of 90.19%, DOCS belongs to the top of the industry, outperforming 97.30% of the companies in the same industry.
DOCS's Gross Margin has been stable in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 40.58% | ||
| PM (TTM) | 36.6% | ||
| GM | 90.19% |
OM growth 3Y11.94%
OM growth 5Y35.03%
PM growth 3Y43.8%
PM growth 5Y113.48%
GM growth 3Y1.71%
GM growth 5Y0.47%
2. Health
2.1 Basic Checks
DOCS has a Return on Invested Capital (ROIC), which is just above the Cost of Capital (WACC), which means it is creating some value.
There is no outstanding debt for DOCS. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
2.2 Solvency
An Altman-Z score of 44.50 indicates that DOCS is not in any danger for bankruptcy at the moment.
DOCS has a Altman-Z score of 44.50. This is amongst the best in the industry. DOCS outperforms 97.30% of its industry peers.
DOCS has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Altman-Z | 44.5 |
ROIC/WACC1.64
WACC10.63%
2.3 Liquidity
A Current Ratio of 8.74 indicates that DOCS has no problem at all paying its short term obligations.
Looking at the Current ratio, with a value of 8.74, DOCS belongs to the top of the industry, outperforming 94.59% of the companies in the same industry.
A Quick Ratio of 8.74 indicates that DOCS has no problem at all paying its short term obligations.
Looking at the Quick ratio, with a value of 8.74, DOCS belongs to the top of the industry, outperforming 94.59% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 8.74 | ||
| Quick Ratio | 8.74 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 48.42% over the past year.
Measured over the past years, DOCS shows a very strong growth in Earnings Per Share. The EPS has been growing by 20.79% on average per year.
EPS 1Y (TTM)48.42%
EPS 3Y20.79%
EPS 5YN/A
EPS Q2Q%52%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%17.14%
3.2 Future
DOCS is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 13.99% yearly.
DOCS is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 14.51% yearly.
EPS Next Y-5.27%
EPS Next 2Y1.2%
EPS Next 3Y5.16%
EPS Next 5Y13.99%
Revenue Next Year12.16%
Revenue Next 2Y12.17%
Revenue Next 3Y12.28%
Revenue Next 5Y14.51%
3.3 Evolution
The estimated forward EPS growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
4. Valuation
4.1 Price/Earnings Ratio
Based on the Price/Earnings ratio of 36.23, the valuation of DOCS can be described as expensive.
DOCS's Price/Earnings ratio is a bit cheaper when compared to the industry. DOCS is cheaper than 78.38% of the companies in the same industry.
The average S&P500 Price/Earnings ratio is at 26.60. DOCS is valued slightly more expensive when compared to this.
A Price/Forward Earnings ratio of 38.24 indicates a quite expensive valuation of DOCS.
70.27% of the companies in the same industry are more expensive than DOCS, based on the Price/Forward Earnings ratio.
The average S&P500 Price/Forward Earnings ratio is at 22.43. DOCS is valued rather expensively when compared to this.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 36.23 | ||
| Fwd PE | 38.24 |
4.2 Price Multiples
DOCS's Enterprise Value to EBITDA ratio is a bit cheaper when compared to the industry. DOCS is cheaper than 70.27% of the companies in the same industry.
Based on the Price/Free Cash Flow ratio, DOCS is valued a bit cheaper than 70.27% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 41.3 | ||
| EV/EBITDA | 36.04 |
4.3 Compensation for Growth
The excellent profitability rating of DOCS may justify a higher PE ratio.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y1.2%
EPS Next 3Y5.16%
5. Dividend
5.1 Amount
No dividends for DOCS!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
NYSE:DOCS (5/21/2025, 2:56:05 PM)
51.08
-1.92 (-3.62%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Technology
Earnings (Last)
Earnings (Next)
Inst Owners89.69%
Inst Owner Change6.46%
Ins Owners2.3%
Ins Owner Change-1.98%
Market Cap9.58B
Analysts74.62
Price Target73.68 (44.24%)
Short Float %6.91%
Short Ratio3.96
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)23.24%
Min EPS beat(2)15.86%
Max EPS beat(2)30.62%
EPS beat(4)4
Avg EPS beat(4)23.59%
Min EPS beat(4)15.86%
Max EPS beat(4)30.62%
EPS beat(8)8
Avg EPS beat(8)22.02%
EPS beat(12)12
Avg EPS beat(12)23%
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)2
Avg Revenue beat(2)6.83%
Min Revenue beat(2)5.51%
Max Revenue beat(2)8.16%
Revenue beat(4)3
Avg Revenue beat(4)4.17%
Min Revenue beat(4)-0.57%
Max Revenue beat(4)8.16%
Revenue beat(8)5
Avg Revenue beat(8)2.53%
Revenue beat(12)8
Avg Revenue beat(12)1.92%
Revenue beat(16)11
Avg Revenue beat(16)1.76%
PT rev (1m)-4.14%
PT rev (3m)30.81%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0.65%
EPS NY rev (1m)-31.14%
EPS NY rev (3m)-30.2%
Revenue NQ rev (1m)-0.22%
Revenue NQ rev (3m)0.69%
Revenue NY rev (1m)-0.05%
Revenue NY rev (3m)4.78%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 36.23 | ||
| Fwd PE | 38.24 | ||
| P/S | 17.42 | ||
| P/FCF | 41.3 | ||
| P/OCF | 40.15 | ||
| P/B | 9.3 | ||
| P/tB | 10.21 | ||
| EV/EBITDA | 36.04 |
EPS(TTM)1.41
EY2.76%
EPS(NY)1.34
Fwd EY2.61%
FCF(TTM)1.24
FCFY2.42%
OCF(TTM)1.27
OCFY2.49%
SpS2.93
BVpS5.5
TBVpS5
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 17.18% | ||
| ROE | 19.53% | ||
| ROCE | 21.14% | ||
| ROIC | 17.38% | ||
| ROICexc | 86.87% | ||
| ROICexgc | 153.93% | ||
| OM | 40.58% | ||
| PM (TTM) | 36.6% | ||
| GM | 90.19% | ||
| FCFM | 42.18% |
ROA(3y)12.35%
ROA(5y)10.68%
ROE(3y)14.41%
ROE(5y)14.17%
ROIC(3y)12.02%
ROIC(5y)17.46%
ROICexc(3y)87.69%
ROICexc(5y)N/A
ROICexgc(3y)180.49%
ROICexgc(5y)N/A
ROCE(3y)14.62%
ROCE(5y)21.23%
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3Y-48.43%
ROICexc growth 5YN/A
OM growth 3Y11.94%
OM growth 5Y35.03%
PM growth 3Y43.8%
PM growth 5Y113.48%
GM growth 3Y1.71%
GM growth 5Y0.47%
F-Score9
Asset Turnover0.47
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Debt/EBITDA | 0 | ||
| Cap/Depr | 64.1% | ||
| Cap/Sales | 1.21% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 102.17% | ||
| Profit Quality | 115.26% | ||
| Current Ratio | 8.74 | ||
| Quick Ratio | 8.74 | ||
| Altman-Z | 44.5 |
F-Score9
WACC10.63%
ROIC/WACC1.64
Cap/Depr(3y)76.9%
Cap/Depr(5y)164.34%
Cap/Sales(3y)1.45%
Cap/Sales(5y)2.04%
Profit Quality(3y)121.74%
Profit Quality(5y)186.38%
High Growth Momentum
Growth
EPS 1Y (TTM)48.42%
EPS 3Y20.79%
EPS 5YN/A
EPS Q2Q%52%
EPS Next Y-5.27%
EPS Next 2Y1.2%
EPS Next 3Y5.16%
EPS Next 5Y13.99%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%17.14%
Revenue Next Year12.16%
Revenue Next 2Y12.17%
Revenue Next 3Y12.28%
Revenue Next 5Y14.51%
EBIT growth 1Y37.19%
EBIT growth 3Y47.72%
EBIT growth 5Y90.21%
EBIT Next Year41.37%
EBIT Next 3Y20.99%
EBIT Next 5Y19.89%
FCF growth 1Y34.38%
FCF growth 3Y31.5%
FCF growth 5Y66.11%
OCF growth 1Y32.62%
OCF growth 3Y30.41%
OCF growth 5Y64.46%